• 대한한방부인과학회지
• /
• 제27권4호
• /
• pp.1-14
• /
• 2014

Objectives: This study was designed to investigate the anti-tumor metastasis by anti-inflammatory and innate immunomodulating effects of extracts of Jipae-san on cancer cells. Methods: Antimetastatic experiments were conducted in vivo mouse model by using 4T1 mouse mammary carcinoma cells. Cell viability of Jipae-san was tested with 4T1 mouse mammary carcinoma cells, colon 26-M3.1 carcinoma cells and macrophage. In addition expression of $TNF-{\alpha}$ and NO induced by LPS was measured after treating with Jipae-san. To observe innate immunomodulating effects of Jipae-san on macrophage, we measured $TNF-{\alpha}$, IL-12, IL-6 and MCP-1, respectively. Cell cytotoxicity was tested with the macrophage stimulated with Jipae-san and we evaluated the activation of $TNF-{\alpha}$ and NO. And the effect of Jipae-san on metastasis was measured without NK-cell using GM1 serum. Results: Intravenous inoculation of Jipae-san significantly inhibited metastasis of 4T1 mouse mammary carcinoma cells. In an in vitro cytotoxicity analysis, cell growth are closer to 100% less than $1,000{\mu}g/ml$ concentration. The expression of $TNF-{\alpha}$ and NO induced by LPS after treating Jipae-san was down regulated in dose-dependent manner. Level of cytokines such as $TNF-{\alpha}$, IL-12, IL-6 and MCP-1 of Jipae-san group were up regulated in compared to the control group. The macrophage stimulated with Jipae-san significantly inhibits the cancer cell at ratio of 10:1, 20:1. The activation of NO was significantly up regualted in a group of 5:1, 10:1, 20:1. The depletion of NK-cells by anti-asialo GM1 serum partly abolished the inhibitory effect of Jipae-san on tumor metastasis. Conclusions: Jipae-san appears to have considerable activity on the anti-metastasis by inflammation control and activation of innate immune system.

• 대한한방내과학회지
• /
• 제43권4호
• /
• pp.559-566
• /
• 2022

서론: 본 체계적 문헌 고찰의 프로토콜 논문은 간암의 한약 치료에 대한 효과와 안전성의 근거를 제시하는 것을 목표로 한다. 방법: 본 체계적 문헌 고찰은 간암에 한약 치료에 대한 무작위 대조 임상시험을 포함할 것이다. 오직 무작위 대조 임상시험 유형의 임상 연구만 포함할 것이다. 시험군의 한약 치료는 한약을 사용한 모든 제형을 포함할 것이며, 대조군은 다른 치료, 플라시보 치료, 서양의학적 치료 등을 포함할 것이다. 다음 11개의 데이터베이스를 활용하여 검색할 것이다: the Cochrane Database of Systematic Reviews, MEDLINE, EMBASE, AMED, CINAHL, Chinese database(CNKI), 그리고 다섯 개의 한국데이터베이스(OASIS, DBpia, RISS, KISS, and NDSL). 연구의 선정, 데이터 추출 및 분석 등의 업무는 3명의 연구자가 독립적으로 수행할 것이다. 비뚤림 위험 평가를 포함한 연구의 질적 평가는 Cochrane risk-of-bias assessment tool을 사용할 것이다. 결과: 본 간암에 대한 한약 치료의 체계적 문헌 고찰은 최신의 근거를 요약적이고 분석적으로 제공할 것이다. 결론: 간암의 한약 치료에 대한 효과와 안전성의 근거를 제시할 것이며, 이는 종양학이나 한의학과 보완·대체의료 분야의 종사자들에게 유용한 정보를 제공할 것이다.

• 문화기술의 융합
• /
• 제8권5호
• /
• pp.71-80
• /
• 2022

본 연구는 국내·외 경도인지장애 노인에게 시행된 비약물 중재의 우울 증상에 대한 효과를 확인하기 위해 시행되었다. PubMed, CINAHL, PsycINFO, Science direct, KISS, RISS, DBPia 등의 전자 데이터베이스를 통해 총1,147편의 문헌을 검색하였고 문헌선정 기준을 충족하는 21편의 문헌이 선정되었다. 선정된 문헌의 질평가는 2명의연구자가 독립적으로 시행하였다. 비약물 중재의 효과크기는 CMA3.0 프로그램을 이용하여 분석하였고, 분석결과 비약물 중재의 우울 증상에 대한 전체 효과크기는 중간효과크기(ES=-0.68)로 나타났다. 하위그룹 분석결과, 인지중재(ES=-1.03)와 복합중재(ES=-0.97)가 운동중재(ES=-0.53)에 비해 큰 효과크기를 나타냈다. 본 연구결과 비약물 중재가 경도인지장애 노인의 우울 증상 감소에 효과적임이 확인되었으며, 이를 토대로 경도인지장애 노인의 인지기능과 우울 증상 개선을 위한 다양한 비약물 중재프로그램이 시행되기를 기대한다.

• 대한한방내과학회지
• /
• 제44권3호
• /
• pp.366-386
• /
• 2023

Objective: In this study, a questionnaire survey was conducted for doctors and patients to obtain basic data necessary for the development of an integrated medical system for idiopathic pulmonary fibrosis (IPF). Methods: Questionnaires were developed separately for doctors and patients through an expert group meeting. The survey subjects were recruited online and offline, and finally, responses from 231 doctors and 59 patients were used for statistical analysis. Results: The most important parts in the treatment of IPF for both doctors and patients were the "improvement of respiratory symptoms," "improvement of quality of life," and "prevention of disease progression." Antifibrotic agents were prescribed at a high rate, and 100% of the specialists in Western medicine (WM) and 45.8% of patients reported experiencing side effects. As for the additional payment costs that patients considered as affordable for an integrated medical system, "under 50,000 won (about 38$)" was reported the most in both doctor and patient groups. With regard to the reasons for their reluctance to recommend an integrated medical system for IPF, specialists in WM responded highly to "uncertain evidence for treatment effectiveness." Regarding complementary and alternative medicine therapies that can be beneficial in patients with IPF, "lifestyle management," "diet management," "herb," "relaxation therapy," and "psychotherapy" were ranked high in both doctor and patient groups. Conclusions: In this study, a questionnaire survey on IPF was conducted to review actual treatment status, analyze shortcomings, and identify considerations for the development of an integrated medical system for IPF in the future.